<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88158">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957436</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1105 GETUG AFU-21</org_study_id>
    <nct_id>NCT01957436</nct_id>
  </id_info>
  <brief_title>A Phase III of ADT +/- Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.</brief_title>
  <acronym>PEACE1</acronym>
  <official_title>A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase III study to compare the clinical benefit of androgen
      deprivation therapy (+/- docetaxel) with or without local radiotherapy with or without
      abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomize in the trial after his consent form has been signed, and
      after all inclusion and non-inclusion criteria have been checked.

      The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone),
      arm C(ADT + radiotherapy) or arm D (ADT + Abiraterone + radiotherapy) in a 1:1:1:1 ratio.

      The randomization will be stratified (by minimization) according to:

        -  enrolment center,

        -  performance status (0 vs. 1-2)

        -  disease extent: lymph nodes only vs. bone (with or without lymph nodes) vs. presence of
           visceral metastases.

      CRPC is defined by cancer progression (either a confirmed PSA rise or a radiological
      progression) with serum testosterone being at castrated levels (&lt;0.50 ng/mL).

      When the CRPC stage is reached, castration (either LHRH agonist or LHRH antagonist) will be
      maintained in all patients. Patients from arm B and D will then stop abiraterone (in
      selected cases e.g. slow/asymptomatic progressions, the investigator may consider continuing
      ADT + abirateroneprednisone at CRPC, rather than switching directly to another therapy, for
      patients included in the abiraterone arms, the use of prednisone at this stage is left to
      the investigator decision).

      Investigators will be free to manage patients reaching CRPC at their discretion (using for
      example docetaxel, zoledronic acid, denosumab, sipuleucel-T, radium-223, cabazitaxel, etc)
      according to local uses and guidelines. Abiraterone may be used in arm A and C if
      abiraterone has become the standard treatment for CRPC when this stage is reached.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5.5 years after the first inclusion</time_frame>
    <description>Overall and progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>8 months</time_frame>
    <description>The PSA response rate will be defined by an undetectable serum PSA level at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective correlative study of PSA response/progression</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>5.5 years</time_frame>
    <description>will be evaluated by questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next skeletal-related event</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chemotherapy</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to severe local symptoms</measure>
    <time_frame>5.5 years</time_frame>
    <description>The time to severe local symptoms (grade 3 and 4 events) related to tumor progression and/or radiotherapy long term side effects will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5.5 years</time_frame>
    <description>Toxicity (with a specific focus on the use of long-term low-dose steroids) will be evaluated according to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The radiological progression-free survival</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of radiotherapy protocol on outcome</measure>
    <time_frame>5.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">916</enrollment>
  <condition>Prostate Cancer Adenocarcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>androgen deprivation therapy (+/- docetaxel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>androgen deprivation therapy + abiraterone acetate + prednisone (+/- docetaxel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A + radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B + radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone acetate</intervention_name>
    <description>abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Androgen Deprivation Therapy</intervention_name>
    <description>The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 cycles at 75mg/m²/cycle, one cycle every 3 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed adenocarcinoma of the prostate,

          2. Metastatic disease documented by positive bone scan or CTscan or MRI. For patients
             with nodal metastases only, only patients with extra-pelvic enlarged lymph nodes can
             be included if they have either:

               -  At least one extra-pelvic lymph node ≥ 2 cm or

               -  extra-pelvic lymph node (s) ≥ 1 cm if the patients also have at least one pelvic
                  lymph node ≥ 2 cm

          3. Patients with ECOG ≤ 1 (PS 2 due to bone pain accepted),

          4. Life expectancy ≥ 6 months,

          5. Male aged ≥ 18 years old,

          6. Hemoglobin ≥ 10.0 g/dL,

          7. Platelet count ≥ 100,000/μL,

          8. Serum creatinine &lt; 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min,

          9. Serum potassium ≥ 4.0 mmol/L,

         10. Serum bilirubin ≤ 1.5 x ULN (except documented Gilbert's disease); AST and ALT ≤ 2.5
             x ULN (≤ 5 ULN in case of liver metastases),

         11. Patients might have received a maximum of 3 months of ADT before randomization,

         12. Patients might have received previous radiation therapy directed to bone lesions

         13. Patients able to take oral medication,

         14. Patients who have received the information sheet and signed the informed consent
             form,

         15. Male patients who are receiving the study treatment and have partners of childbearing
             potential are advised to use a method of birth control with adequate barrier
             protection (condoms) as determined to be acceptable by the study doctor during the
             treatment period and for 4 weeks after the last dose of the study treatment.

         16. Patients must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests and other study procedures,

         17. Patients with a public or a private health insurance coverage,

             Additional criteria for patients receiving docetaxel:

         18. Patients willing to receive docetaxel

         19. Neutrophil ≥ 1500 cells/mm3

         20. Liver function: AST and ALT ≤ 1.5 x ULN; ALP ≤ 2.5 x ULN; Serum bilirubin ≤ 1.5 x
             ULN.

         21. Male patients who will receive docetaxel and have partners of childbearing potential
             and/or pregnant partners are advised to use a method of birth control in addition to
             an adequate barrier protection (condoms) as determined to be acceptable by the study
             doctor during the treatment period and for 6 months after the last dose of docetaxel.

        Exclusion Criteria:

          1. Patients with previous local treatment directed to the prostate primary cancer. A
             previous TURP is allowed,

          2. Prior cytotoxic chemotherapy or biological therapy for the treatment of prostate
             cancer,

          3. Any chronic medical condition requiring a higher dose of corticosteroid than 5mg
             prednisone/prednisolone twice daily,

          4. Active infection or other medical condition for which corticosteroid use would be
             contraindicated,

          5. Previously treated with ketoconazole for prostate cancer for more than 7 days,

          6. Prior systemic treatment with an azole drug within 4 weeks of randomization,

          7. Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg),

          8. Patients with a history of hypertension except if blood pressure is controlled by
             anti-hypertensive treatment,

          9. Active or symptomatic viral hepatitis or chronic liver disease (except Gilbert's
             disease),

         10. History of pituitary or adrenal dysfunction,

         11. Small cell carcinoma of the prostate,

         12. Clinically known significant heart disease (myocardial infarction, arterial
             thrombotic events in the past 6 months, severe or unstable angina,NYHA Class II-IV
             heart disease or cardiac EF &lt; 50% at baseline,

         13. Atrial Fibrillation, or other cardiac arrhythmia requiring therapy,

         14. Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of
             recurrence within 24 months,

         15. Known allergies, hypersensitivity or intolerance to the study drugs or excipients,

         16. Administration of an investigational therapeutic within 30 days of D1,

         17. Patients already included in another therapeutic trial involving an experimental
             drug,

         18. Patients with significantly altered mental status prohibiting the understanding of
             the study or with psychological, familial, sociological or geographical condition
             potentially hampering participation,

         19. Individual deprived of liberty or placed under the authority of a tutor.

        Additional criteria for patients receiving docetaxel:

        21. Patients with impaired vision should undergo a prompt and complete ophthalmologic
        examination. In case of Cystoid Macular Oeadema, the patient should not receive docetaxel.

        22. Concomitant use of strong CYP3A4 inhibitors ( clarithromycin, indinavir, nefazodone,
        nelfinavir, ritonavir, saquinavir, telithromycin) 23. Allergy to taxane
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris - Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beata JUZYNA</last_name>
    <email>b-juzyna@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire JOUFFROY</last_name>
    <email>c-jouffroy@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter SCHATTEMAN</last_name>
    </contact>
    <investigator>
      <last_name>Peter SCHATTEMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet Erasme- Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry GIL</last_name>
    </contact>
    <investigator>
      <last_name>Thierry GIL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine Saint Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick NEYBUCH</last_name>
    </contact>
    <investigator>
      <last_name>Yannick NEYBUCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace BILLIET</last_name>
    </contact>
    <investigator>
      <last_name>Ignace BILLIET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand TOMBAL</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand TOMBAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Louvain</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand TOMBAL</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand TOMBAL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GasthuisZusters Antwerpen - Sint - Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>ANGERS Cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE</last_name>
      <phone>+33(0)2 41 35 27 00</phone>
      <email>sophie.abadie-lacourtoisie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Générale d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Pays Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien BLOUET</last_name>
      <phone>+33(0)5 59 59 38 71</phone>
      <email>aurelien.blouet@oncologie-pays-basque.org</email>
    </contact>
    <investigator>
      <last_name>Aurélien BLOUET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan MAURINA</last_name>
      <phone>+33(0)3 81 66 87 96</phone>
      <email>t1maurina@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Tristan MAURINA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem ROUBAUD</last_name>
      <phone>+33(0)5 56 33 33 33</phone>
      <email>g.roubaud@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Guilhem ROUBAUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali HASBINI</last_name>
      <phone>+33(0)2 98 31 32 00</phone>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Ali HASBINI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlon SILVA</last_name>
    </contact>
    <investigator>
      <last_name>Marlon SILVA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Chalon Sur Saone</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin SCHIPMAN</last_name>
      <phone>+33(0)6 43 38 22 11</phone>
      <email>benschipman@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin SCHIPMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Leman</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol ALLIOT</last_name>
      <phone>+33(0)4 50 82 22 70</phone>
      <email>calliot@ch-alpes-leman.fr</email>
    </contact>
    <investigator>
      <last_name>Carol ALLIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SERA</name>
      <address>
        <city>Contamine Sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique LOISEAU</last_name>
      <phone>+33(0)6 60 63 56 28</phone>
      <email>domloiseau@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique LOISEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazid BELKACEMI</last_name>
      <phone>+33(0)1 49 81 45 22</phone>
      <email>yazid.belkacemi@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Yazid BELKACEMI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François LECLERC</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN</last_name>
      <phone>+33(0)3 80 73 75 18</phone>
      <email>emartin@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Etienne MARTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Marguerite</name>
      <address>
        <city>Hyères</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François BERDAH</last_name>
      <phone>+33(0)4 94 12 55 60</phone>
      <email>jf.berdah@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François BERDAH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La ROCHE sur YON</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank PRIOU</last_name>
      <phone>+33(0)2 51 44 61 73</phone>
      <email>frank.priou@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Frank PRIOU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric VOOG</last_name>
      <phone>+33(0)2 43 29 79 08</phone>
      <email>e.voog@cjb72.org</email>
    </contact>
    <investigator>
      <last_name>Eric VOOG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre CLAVERE</last_name>
      <phone>+33(0)5 55 05 62 68</phone>
      <email>pierre.clavere@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre CLAVERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON</last_name>
      <phone>+33(0)4 78 78 26 43</phone>
      <email>aude.flechon@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aude FLECHON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Timone</name>
      <address>
        <city>MARSEILLE Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xavier MURACCIOLE</last_name>
      <phone>+33(0)4 91 38 43 34</phone>
      <email>xavier.muracciole@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>xavier MURACCIOLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaëlle GRAVIS</last_name>
      <phone>+33(0)4 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaëlle GRAVIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe RONCHIN</last_name>
      <phone>+33(0)4 94 52 11 82</phone>
      <email>ronchinp@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe RONCHIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude EL KOURI</last_name>
      <phone>+33(0)2 28 27 21 66</phone>
      <email>elkouri.claude@catherinedesienne.fr</email>
    </contact>
    <investigator>
      <last_name>Claude EL KOURI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Eve CHAND-FOUCHE</last_name>
      <phone>+33(0)4 92 03 12 70</phone>
      <email>marie-eve.chand@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Eve CHAND-FOUCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>NIMES Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane DROUPY</last_name>
      <phone>+33(0)4 66 68 33 51</phone>
      <email>stephane.droupy@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane DROUPY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Orléans la source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Champeaux-Orange</last_name>
      <phone>+33(0)2 38 51 47 78</phone>
      <email>elise.champeaux-orange@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Elise Champeaux-Orange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BEUZEBOC</last_name>
      <phone>+33(0)1 44 32 46 80</phone>
      <email>philippe.beuzeboc@curie.net</email>
    </contact>
    <investigator>
      <last_name>Philippe BEUZEBOC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN</last_name>
      <phone>+33(0)1 42 49 90 24</phone>
      <email>christophe.hennequin@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe HENNEQUIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chic Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike SCHLURMANN</last_name>
      <phone>+33(0)2 90 26 45 59</phone>
      <email>friederike.schlurmann@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Friederike SCHLURMANN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51726</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>RENNES Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte LAGUERRE</last_name>
      <phone>+33(0)2 99 25 31 82</phone>
      <email>b.laguerre@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte LAGUERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian PFISTER</last_name>
      <phone>+33(0)2 32 88 81 63</phone>
      <email>christian.pfister@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Christian PFISTER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte VIE</last_name>
      <phone>+33(0)2 96 75 22 20</phone>
      <email>b.vie@clin-armoricaine.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte VIE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU ST ETIENNE - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>44270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MOTTET-AUSELO</last_name>
      <phone>+33(0)4 77 82 83 31</phone>
      <email>nicolas.mottet@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MOTTET-AUSELO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ARTIGNAN</last_name>
      <phone>+33(0)2 99 54 09 49</phone>
      <email>xartignan@vivalto-sante.com</email>
    </contact>
    <investigator>
      <last_name>Xavier ARTIGNAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie del'Ouest - site René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane SUPIOT</last_name>
      <phone>+33(0)2 40 67 99 13</phone>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane SUPIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy DE LAROCHE</last_name>
      <phone>+33(0)4 77 91 71 02</phone>
      <email>guy.delaroche@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Guy DE LAROCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strasbourg Oncologie Libérale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne ESCANDE</last_name>
      <phone>+33(0)3 88 45 37 50</phone>
      <email>aescande@neuf.fr</email>
    </contact>
    <investigator>
      <last_name>Anne ESCANDE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Luc LANDRY</last_name>
      <phone>+33(0)4 50 83 23 67</phone>
      <email>j-landry@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Luc LANDRY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer - Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GUILLET</last_name>
      <phone>+33(0)4 94 14 58 35</phone>
      <email>pierre.guillet@ch-toulon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre GUILLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>TOULOUSE Cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF</last_name>
      <phone>+33(0)5 67 20 44 00</phone>
      <email>i.latorzeff@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Igor LATORZEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>TOULOUSE Cedex</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc MOUREY</last_name>
      <phone>+33(0)5 61 42 41 20</phone>
      <email>mourey.loic@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc MOUREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INSTITUT GUSTAVE ROUSSY, Cancer Campus, Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Fizazi</last_name>
      <phone>+33(0)1 42 11 62 64</phone>
      <email>karim.fizazi@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Karim Fizazi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul KELLY</last_name>
    </contact>
    <investigator>
      <last_name>Paul KELLY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath incorporating National Children's hospital department</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac DERMOTT</last_name>
    </contact>
    <investigator>
      <last_name>Mac DERMOTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac CAFFREY</last_name>
    </contact>
    <investigator>
      <last_name>Mac CAFFREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac CAFFREY</last_name>
    </contact>
    <investigator>
      <last_name>Mac CAFFREY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac DERMOTT</last_name>
    </contact>
    <investigator>
      <last_name>Mac DERMOTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DR SMALL</last_name>
    </contact>
    <investigator>
      <last_name>DR SMALL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sc Radiotherapy Center Cluj SRL</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel KACSO</last_name>
    </contact>
    <investigator>
      <last_name>Gabriel KACSO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador VILLA FREIXA</last_name>
    </contact>
    <investigator>
      <last_name>Salvador VILLA FREIXA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta GUIX ARNAU</last_name>
    </contact>
    <investigator>
      <last_name>Marta GUIX ARNAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MALDONADO</last_name>
    </contact>
    <investigator>
      <last_name>Xavier MALDONADO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona - Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 OCTUBRE</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Althaia</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Montserrat DOMENECH</last_name>
    </contact>
    <investigator>
      <last_name>Montserrat DOMENECH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel CLIMENT</last_name>
    </contact>
    <investigator>
      <last_name>Miguel CLIMENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 18, 2016</lastchanged_date>
  <firstreceived_date>September 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic hormone-naive</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>abiraterone acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
